SCIENTIFIC REPORT 2004 - Sylvester Comprehensive Cancer Center

More documents

Recommendations

Info

I N T R O D U C T I O N A N D P R O G R E S S R E P O R T Hugo F. Fernandez, M.D., have initiated a clinical trial using SGN30 in lymphoma patients. UM/Sylvester has collaborated with Seattle Genetics to further the investigation of SGN30. • The future of cancer treatment also may use vaccines to boost the immune system so it recognizes and kills cancer cells. Luis E. Raez, M.D., F.A.C.P., and Richard J. Thurer, M.D., are among the physicians working with UM/Sylvester physician-scientist Eckhard R. Podack, M.D., Ph.D., to develop several new revolutionary vaccines for the treatment of lung cancer. This approach also may lead to vaccines for other cancers. Dr. Thurer is a professor of Surgery and director of the Thoracic Surgery Section. • Joseph D. Rosenblatt, M.D., UM/Sylvester’s Associate Director, Clinical and Translational Research and Division Chief of Hematology- Oncology, opened a phase I clinical trial of a novel combination therapy for patients with certain types of leukemia and lymphoma. The idea of this trial is to use an antibody, which has had some success in the treatment of these disorders, and to try and augment the effects of that antibody in combination with interleukin-2 (IL-2). Campath-1H, also called alemtuzumab, is an approved form of treatment for patients with efractory/relapsed B-cell chronic lymphocytic leukemia, T-prolymphocytic leukemia, and cutaneous T-cell lymphomas (Sezary syndrome). By using IL-2 and alemtuzumab in combination it may hasten the return of the immune system to normal by enhancing the recovery of T cells and reducing post-treatment infectious complications. The idea of combining these two drugs was developed by Dr. Rosenblatt, Edgardo Santos, M.D., and their colleagues in the department of Medicine at the University of Miami School of Medicine. • Joseph D. Rosenblatt also is leading studies related to the development of novel immunotherapeutic and gene therapy strategies for human malignancy. Dr. Rosenblatt and Khaled Tolba, M.D., assistant professor of Medicine, have studied the ability of gene therapy “vectors” derived from herpes simplex virus called HSV amplicons to augment the immune response to tumors. Together with Seung-Uon Shin, Ph.D., an expert in antibody engineering, Dr. Rosenblatt’s laboratory has developed a variety of antibody fusion proteins with potential utility in human malignancy. These include fusions with immune effector molecules such as T-cell costimulatory ligands, and/or molecules that can recruit immune cells such as chemokines. Dr. Shin also is studying a fusion of anti-tumor antibody with an antiangiogenic agent called endostatin, which improves upon the performance of either an anti-her2/neu antibody or endostatin alone in the setting of breast cancer in preclinical tumor models. • Joyce M. Slingerland, M.D., Ph.D., professor of Medicine, is directing research efforts in breast cancer and also serves as director of the Braman Family Breast Cancer Institute at UM/Sylvester, a multidisciplinary translational research institute devoted to advancing research in cancer prevention, diagnosis, and treatment. Dr. Slingerland is a recognized authority on cell cycle regulation in relation to breast cancer, with particular emphasis on the p27 cell cycle regulator. She heads a major laboratory effort and has continued to recruit key individuals to increase expertise in the areas of molecular pathology, epidemiology, and clinical trials in breast cancer. UM/Sylvester Comprehensive Cancer Center Scientific Report 2004 v
I N T R O D U C T I O N A N D P R O G R E S S R E P O R T National Cancer Institute Designation I am pleased to tell you that UM/Sylvester will seek National Cancer Institute designation in 2005. Comprised of a distinguished group of physicians and scientists, the External Advisory Committee has visited UM/Sylvester twice within the past year to evaluate the progress in our multidisciplinary research programs and research initiatives. They were highly complimentary of UM/Sylvester’s continuing efforts and recommended application for the NCI-Comprehensive Cancer Center designation next year. The EAC will meet with us again during the fall of 2004; their advice and assistance has been invaluable. Research is curing cancer, and to further achieve that goal, UM/Sylvester continues to build upon its excellent multidisciplinary research programs and shared resources already in place. We are especially invested in the development of home grown clinical trials based on science and technology developed at the University of Miami. We continue working to bring research discoveries from the laboratory bench to the patient bedside more quickly than ever before. In Closing These are exciting times at UM/Sylvester, and I am proud to be part of such a dynamic and dedicated team. Together with support from our senior vice president for medical affairs and dean of the school of medicine, John G. Clarkson, M.D., and University of Miami President Donna E. Shalala, Ph.D., we take steps toward winning the war against cancer every day. We also work very hard to ensure the best possible quality of life for our patients. But we must continue to do more. I hope you find this report interesting and inspiring. I want to assure you that UM/Sylvester, South Florida’s only university-based cancer center, is making a difference in the lives of South Florida citizens and that we are committed to this noble cause. Thank you for your time and attention. W. Jarrard Goodwin, M.D., F.A.C.S. Director University of Miami Sylvester Comprehensive Cancer Center 1 NCI: http://www.cancer.gov and the SEER Homepage: http://www.seer.cancer.gov. Click on “1975-2001 Report to the Nation.” vi UM/Sylvester Comprehensive Cancer Center Scientific Report 2004
Page 1 and 2: S C I E N T I F I C R E P O R T 2 0
Page 3 and 4: I N T R O D U C T I O N A N D P R O
Page 5 and 6: I N T R O D U C T I O N A N D P R O
Page 7: I N T R O D U C T I O N A N D P R O
Page 11 and 12: L E A D E R S H I P MULTIDISCIPLINA
Page 13 and 14: L E A D E R S H I P EXTERNAL ADVISO
Page 15 and 16: C A N C E R P R E V E N T I O N A N
Page 47 and 48: C L I N I C A L O N C O L O G Y R E
Page 59 and 60:
C L I N I C A L O N C O L O G Y R E
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
T U M O R C E L L B I O L O G Y P R
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
T U M O R I M M U N O L O G Y P R O
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
V I R A L O N C O L O G Y P R O G R
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
S H A R E D R E S O U R C E S 3) La
Page 159 and 160:
S H A R E D R E S O U R C E S C E L
Page 161 and 162:
S H A R E D R E S O U R C E S D N A
Page 163 and 164:
S H A R E D R E S O U R C E S G E N
Page 165 and 166:
S H A R E D R E S O U R C E S I N F
Page 167 and 168:
S H A R E D R E S O U R C E S P O P
Page 169 and 170:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 171 and 172:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 173 and 174:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 175 and 176:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 177 and 178:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 179 and 180:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 181 and 182:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 183 and 184:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 185 and 186:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 187 and 188:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 189 and 190:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 191 and 192:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 193 and 194:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 195 and 196:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 197 and 198:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 199 and 200:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 201 and 202:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 203 and 204:
P U B L I C A T I O N S 2 0 0 2 - 2
Page 205 and 206:
G L O S S A R Y IFN—interferon IL
show all

SCIENTIFIC REPORT 2004 - Sylvester Comprehensive Cancer Center

Create successful ePaper yourself

Delete template?

Save as template?